X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

12.05.2022 - Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22 Clinical and regulatory updates from ongoing chronic neutropenia Phase 1b study anticipated during 3Q 2022; Waldenström’s macroglobulinemia Phase 1b study ...

Related Keywords

United States ,Boston ,Massachusetts ,Austria ,Vienna ,Wien ,Paula Ragan ,Glenn Schulman ,Exchange Commission ,Development Rd Expenses ,Nasdaq ,Investor Relations Corporate Communications ,Chief Executive Officer ,Bruton Tyrosine ,Kinase Inhibitors ,Cash Equivalents ,Restricted Cash ,Administrative Expenses ,Severe Congenital Neutropenia ,Private Securities Litigation Reform Act ,Tables Follow ,Investor Relations ,Lifesci Advisors ,